Your Conversations about Diabetes-management make a real difference

Talk about tight glycemic control to reduce risks.

Use HbA1c results to achieve therapeutic goals

- The management goal for most patients with diabetes is an HbA1c result between 6% and 7% (1)
- Any improvement in HbA1c levels can be significant (2,3)
- ”The predictive value of HbA1c for total mortality was stronger than that documented for cholesterol concentration, body mass index, and blood pressure.” (4)

What an HBA1c value means in terms of average blood glucose levels.

<table>
<thead>
<tr>
<th>% HbA1c</th>
<th>Level of Control</th>
<th>Average Blood Glucose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>mg/dL</td>
</tr>
<tr>
<td>14.0</td>
<td>Poor Control</td>
<td>330</td>
</tr>
<tr>
<td>13.0</td>
<td></td>
<td>300</td>
</tr>
<tr>
<td>12.0</td>
<td></td>
<td>270</td>
</tr>
<tr>
<td>11.0</td>
<td></td>
<td>240</td>
</tr>
<tr>
<td>10.0</td>
<td>Additional Action Suggested</td>
<td>210</td>
</tr>
<tr>
<td>9.0</td>
<td>Goal</td>
<td>180</td>
</tr>
<tr>
<td>8.0</td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>7.0</td>
<td></td>
<td>120</td>
</tr>
<tr>
<td>6.0</td>
<td></td>
<td>90</td>
</tr>
<tr>
<td>5.0</td>
<td>Normal</td>
<td>60</td>
</tr>
</tbody>
</table>

- With a CV of 2.6%, the DCA 2000 is precise enough to detect even the smallest changes in glycemic control
- DCCT results say (2)
  - Tight glycemic control (~7%)
  - leads to reductions in:
    - Eye disease -76%
    - Nerve disease -60%
    - Cardiovascular disease -41%
    - Kidney disease -39%
- UKPDS results say (3)
  - 1% decrease in HbA1c leads to 35% reduction in risk of microvascular complications

Use microalbuminuria results for telling signs of diabetic nephropathy

- Unique in-office quantitative albumin:creatinine assay compensates for variations in urine concentration
- Allows for early detection, close monitoring and timely interventions in nephropathy
Your patients without diabetes may also want to talk results

- HbA1c testing may give you insight into mortality risks for your non-diabetic patients. (4) "Glycated hemoglobin seems to resemble blood pressure and blood cholesterol in terms of the continuous relation with cardiovascular risk."
- As well, a recent study on urinary albumin levels showed a significant link between future cardiovascular mortality in postmenopausal women. (5) "Microalbuminuria is a reflection of vascular damage and a marker of early arterial disease in women from the general population."

HbA1c – the most accepted metabolic indicator in diabetes

- HbA1c testing should be performed routinely in all patients with diabetes (1). Measure every 3 months to determine whether a patient's metabolic control has remained continuously within the target range.

Microalbuminuria – the standard metabolic indicator for renal disease

- Annual screening for microalbuminuria should begin at diagnosis in patients with type 2 diabetes and after 5 years' disease duration in type 1 diabetes (1).
- "Analyte (albumin) / creatinine ratios should always be measured as part of quantitative measurements if timed collections; overnight or 24-hour (samples) are to be avoided." (6)

HbA1c Testing

- Monoclonal antibody method for HbA1c provides outstanding accuracy and precision.
- Correlation study shows 99% agreement with the HPLC method (7).
- "Near-patient results you can count on – a CV of 2.6%* means your results are reliable." (8)
- National Glycohemoglobin Standardization Program (NGSP) certified method, as recommended by the ADA**

Microalbuminuria Testing

- Microalbuminuria cartridge provides results for both albumin and creatinine.
- Instrument automatically calculates the A:C ratio, so you can use any specimen at any time.

User-friendly operation makes testing simple for you and your patients

- HbA1c results in just 6 minutes
- Microalbuminuria results in just 7 minutes
- Requires only 1µL of capillary/venous whole blood, or 40µL of urine for a test
- Totally self-contained reagent cartridges mean no reagent preparation, mixing or handling.
Immediate results allow immediate interventions

- A recent study indicated that "the immediate feedback provided by the [DCA 2000+ Analyzer] resulted in a significant decrease in HbA1c at 6- and 12-month follow-up...."(7)
- "Immediate access to HbA1c results meant that [healthcare professionals] could make more informed decisions about what changes in management should be implemented. Without immediate access to test results, changes in patient management might be sub-optimal."(8)
- With in-office results, you can discuss next steps with your patients right away - Encourage your patients to continue their successful regimen, or motivate them to begin better managing their diabetes

Make tight diabetes control your focus

- Tighter glycemic control is essential to the effective management of diabetes and its complications
- The precision and accuracy of DCA 2000 HbA1c tests allow you to confidently benchmark your patients, and detect minor changes in their HbA1c levels - Providing your patients with immediate feedback will improve your therapeutic adjustments, and may enhance patient compliance
- The DCA 2000 albumin:creatinine test is accurate enough for you to detect the earliest stages of nephropathy - In-office microalbuminuria results let you monitor your patients' disease management and react quickly
- Using the DCA 2000+, you can provide patients with immediate feedback to improve outcomes

* Average percent CV in normal range
** Most recent certification: as of June, 2001.
DCA 2000 is a registered trademark of Bayer Healthcare LLC.
©2006 Bayer Healthcare LLC. All rights reserved. Printed in Canada

If you want more information, please contact us or your local sales representative.